Slingshot Biosciences

Market position

Described as a supplier of standardized synthetic reference materials in a market where biological cell variability affects reproducibility in flow cytometry and cell therapy quality control [3]. One source frames its positioning against both biological cells and solid-core particles, and connects demand to growth in cell therapy manufacturing and precision diagnostics [3]. No market share or ranking data appear in the sources.

Sources cite polymer-based mimics said to provide greater stability and lot-to-lot consistency than biological cells and solid-core particles, full customizability for specific and rare biomarkers, on-demand manufacturing that scales to any volume, and reduced QC and bridging-study burden [0][3]. Named collaborations with Cerba Research, Prolocor, Fred Hutch, and Cellares are presented as validation of the approach [3]. These claims originate largely from the company and an aggregator profile rather than independent testing data.

Technology

The platform uses biochemistry and polymer chemistry to create synthetic cells (marketed as FlowCytes and TruCytes) that are printed on demand rather than derived from biological sources [0][3]. The company states the mimics offer optical, fluorescent, and biochemical performance suited to cytometry assays, lot-to-lot consistency, tunability to specific phenotypes including rare biomarkers, and semiconductor-like manufacturing scalability [3]. Patent filings referenced in press mentions cover a synthetic human cell mimic particle for cytometric or Coulter devices, engineered particles as red blood cell mimics, and an apoptotic cell mimic [6].

Go-to-market

The company sells through a global sales organization (a Senior Vice President, Global Sales was appointed in March 2026) and maintains a visible conference and trade-show presence, with in-person and webinar events scheduled for 2026 including Advanced Therapies Week, FlowTex, the NWFCS Flow Cytometry Meeting, TRCCC, SoCal Flow Summit, AACR, Advanced Therapies Xchange, ISCT, and CYTO [1][6]. It also publishes technical content such as blog comparisons of biological versus synthetic TBNK immunophenotyping reference materials [0][1], and works through partnerships and collaborations with organizations including Cerba Research, Prolocor, Fred Hutch, and Cellares [3].

Academic and core laboratories, reference and clinical labs, biopharma and CDMOs in cell and gene therapy, cell therapy manufacturers, and instrument manufacturers [1]. End applications span immunology, oncology, gene therapy, diagnostics, and cell therapy manufacturing quality control [3].

Geography

Headquartered in Emeryville, California, US [3][6]. In February 2026 the company announced expansion into the United Kingdom and European Union markets [6]. Scheduled 2026 events span US locations (Boston, Champion PA, Houston, Irvine, San Diego, Seattle, West Palm Beach) and Dublin, Ireland [1].

History

Founded in 2012 [3][6], the company spent an extended period in development before raising a $23M Series A in July 2021 and a further $26M Series A in February 2023 [3]. Product and partnership activity reported for 2025 includes the TruCytes Potency CD20 and CD34 gating control launch and integration work with the Cellares Cell Q platform [3]. In early 2026 the company announced expansion into the UK and EU and the appointment of a Senior Vice President of Global Sales, and several cell-mimic patents were listed among its press mentions [6].

Risks & controversies

No controversies, litigation, or regulatory actions are reported in the available sources. Data quality caveats exist: the aggregator profile lists an employee count of 10,000+ that is not corroborated and appears implausible for a company of this description, classifies the company under Software/AI/Data industries on one platform, and labels both the 2021 and 2023 rounds as "Series A" while a company press-release URL references a "Series A3" financing of $11 million whose details are not retrievable from the fetched page content [1][2][3][4][6]. Leadership listings also conflict between the company site (Glenn Bilawsky as CEO) and third-party profiles (Jeff Kim as CEO and President) [0][3][6]. Financial statements are not publicly disclosed [5].